Virax Biolabs Entered Agreement With H.C. Wainwright For $1.45M At The Market Share Offering
Virax Biolabs Entered Agreement With H.C. Wainwright For $1.45M At The Market Share Offering
On January 22, 2024, Virax Biolabs Group Limited, a Cayman Islands exempted company (the "Company"), entered into an At The Market Offering Agreement (the "Sales Agreement") with H.C. Wainwright & Co., LLC (the "Sales Agent"), acting as the Company's sales agent, pursuant to which the Company may offer and sell, from time to time, through the Sales Agent, its ordinary shares, par value $0.001 per share (the "Ordinary Shares"), having an aggregate offering amount of up to $1,455,029. On January 22, 2024, pursuant to the Sales Agreement, the Company filed a prospectus supplement, including an accompanying base prospectus, dated December 15, 2023, forming a part of its effective registration statement on Form F-3 (File No. 333-275893), initially filed with the Securities and Exchange Commission on December 5, 2023.
2024年1月22日，開曼群島豁免公司（“公司”）Virax Biolabs Group Limited與擔任公司銷售代理的H.C. Wainwright & Co., LLC（“銷售代理”）簽訂了市場發行協議（“銷售協議”），根據該協議，公司可以不時通過銷售代理發行和出售其普通股、面值每股價值0.001美元（“普通股”），總髮行金額最高爲1,455,029美元。2024年1月22日，根據銷售協議，公司於2023年12月15日提交了招股說明書補充文件，包括隨附的基本招股說明書，構成其在F-3表格（文件編號333-275893）上的有效註冊聲明的一部分，該聲明最初於2023年12月5日向美國證券交易委員會提交。